Durlobactam/Sulbactam sodium

Agreement expands access to XACDURO ® for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central America, the Caribbean, Russia and CIS countries (following applicable regional regulatory approvals) The rate of carbapenem resistant -Acinetobacter in these geographies exceeds 70% 1,2 representing substantial unmet need WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, for the development and commercialization of XACDURO ® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use, in South and Central America, the Caribbean, Russia and Commonwealth of Independent States (CIS) countries. In the United States, XACDURO ® is approved and indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). Acinetobacter is a significant public health concern and is classified as a “critical threat” pathogen in World Health Organization global bacterial priority pathogens list 3 . Under the terms of the agreement, Dr. Reddy’s will be responsible for development, regulatory and commercialization activities in the licensed territory. Innoviva Specialty Therapeutics will retain rights to XACDURO in all unlicensed territories and is eligible to receive an upfront payment, regulatory and commercial milestone payments, and tiered royalties on net sales in the licensed territory. “This agreement reflects our ongoing commitment to addressing antimicrobial resistance by expanding access to important therapeutics for patients and healthcare systems facing serious, difficult-to-treat infections,” said Patricia Drake, Chief Commercial Officer of Innoviva Specialty Therapeutics. “Dr. Reddy’s brings strong regional capabilities and experience in infectious disease treatments, and we believe this partnership provides a practical path to broaden XACDURO’s global reach while maintaining our focus on disciplined execution.” XACDURO is the first and only antibiotic approved in the United States in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex ( Acinetobacter ). Acinetobacter infections remain a significant global health challenge, particularly in hospital settings where resistant pathogens can limit available treatment options. The FDA approved XACDURO in May 2023. About XACDURO ® XACDURO ® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use, is a combination of sulbactam, a beta-lactam antibacterial, and durlobactam, a beta-lactamase inhibitor, approved in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex ( Acinetobacter ). XACDURO is not indicated for the treatment of HABP/VABP caused by pathogens other than susceptible isolates of Acinetobacter . Current US FDA approved XACDURO ® INDICATION & USAGE Indication XACDURO ® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use is indicated in adults for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. Limitations of Use XACDURO is not indicated for the treatment of HABP/VABP caused by pathogens other than susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of XACDURO and other antibacterial drugs, XACDURO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. IMPORTANT SAFETY INFORMATION Contraindications : XACDURO is contraindicated in patients with a history of known severe hypersensitivity to the components of XACDURO or other beta-lactam antibacterial drugs. Warnings and Precautions: Hypersensitivity was observed in patients treated with XACDURO in clinical trials. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs. Before initiating therapy with XACDURO, careful inquiry should be made concerning previous hypersensitivity reactions to carbapenems, penicillins, cephalosporins, other beta lactams, and other allergens. If an allergic reaction occurs, discontinue XACDURO. Clostridioides difficile- associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. If CDAD is suspected or confirmed, the risk/benefit of continuing treatment with XACDURO should be assessed. Prescribing XACDURO in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Adverse Reactions: The most common adverse reactions reported in >10% of patients treated with XACDURO were liver test abnormalities (19%), diarrhea (17%), anemia (13%), and hypokalemia (12%). To report SUSPECTED ADVERSE REACTIONS, contact Innoviva Specialty Therapeutics, Inc. at 1-800-651-3861 or FDA at 1-800-FDA-1088 or . Before administering, please see the Full Prescribing Information for XACDURO . About Innoviva Specialty Therapeutics Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., is focused on delivering innovative therapies in critical care and infectious disease. Innoviva Specialty Therapeutics’ products, through its affiliates, include GIAPREZA ® (angiotensin II), XERAVA ® (eravacycline), XACDURO ® (sulbactam for injection; durlobactam for injection), and NUZOLVENCE ® (zoliflodacin). Innoviva Specialty Therapeutics also markets ZEVTERA (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the U.S. through an exclusive license from Basilea Pharmaceutica International Ltd, Allschwil. For more information about Innoviva Specialty Therapeutics, please visit . Forward Looking Statements This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR ® /BREO ® ELLIPTA ® , ANORO ® ELLIPTA ® , GIAPREZA ® , XERAVA ® , XACDURO ® , ZEVTERA ® and NUZOLVENCE ® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the development of the LYNX ® platform; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Reports on Form 10-Q, which are on the Securities and Exchange Commission (“SEC”) and available on the SEC’s website at . Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward looking statements on account of new information, future events or otherwise, except as required by law. ANORO ® , RELVAR ® and BREO ® are trademarks of the GSK group of companies. ZEVTERA is a trademark of Basilea Pharmaceutica International AG, Allschwil. 1 Lavrinenko (2021) Antibiotics 2 Rojas (2026) Antibiotics 3 WHO Bacterial Priority Pathogens List (2024) Contacts Investor and media contact Irwin Tendler Head of Investor Relations Executive Director, Corporate Development investors.relations@inva.com

International Journal of Antimicrobial Agents Volume 67, Issue 1 国际抗微生物制剂杂志 67卷 1期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/1 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会新闻与信息页） 1 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page 国际抗菌化疗学会（ISAC）新闻与信息页 Article 107688 Antimicrobial Pharmacometrics（抗菌药物药代动力学） 2 Model-informed precision pyrazinamide dosing: The establishment of a population pharmacokinetic model repository for clinical decision support 基于模型的精准吡嗪酰胺剂量调整：建立用于临床决策支持的人群药代动力学模型库 Huan Zhang, Lu Han, Xiao-Qin Liu, Juan Wang, ... Zheng Jiao Article 107658 Global Landscape of Phage Therapy（噬菌体治疗的全球概况） 3 Nanomedicine for phage therapy: Encapsulation strategies for enhanced antimicrobial efficacy 噬菌体治疗的纳米医学：增强抗菌功效的封装策略 Alexis Dorta-Gorrín, Verónica Salgueiriño, Lorena García-Hevia Article 107660 4 Antibiotic-mediated prophage activation: Mechanisms, consequences, and therapeutic implications 抗生素介导的原噬菌体激活：机制、后果及治疗意义 Damir Gavric, Petar Knezevic Article 107655 5 Phage therapy for KPC-producing Klebsiella pneumoniae decolonization in high-risk patients: The KIDNAP Study Protocol – A prospective feasibility and proof of concept study in the Brazilian context 噬菌体治疗高风险患者中产KPC肺炎克雷伯菌的定植清除：KIDNAP研究方案——巴西背景下的一项前瞻性可行性及概念验证研究 Iris Najjar, Larissa Simão Gandolpho, Jôiciglecia Pereira dos Santos, Camila de Paula Siqueira, ... Ana C. Gales Article 107673 AI strategies to combat AMR（人工智能对抗抗菌药物耐药性的策略） 6 Development and validation of machine learning models to predict vancomycin- and teicoplanin-associated acute kidney injury: A retrospective, multicenter study 开发和验证机器学习模型用以预测万古霉素和替考拉宁相关的急性肾损伤：一项回顾性、多中心研究 Pin-Yi Lo, Fan-Ying Chan, Yi-En Ku, San-Yuan Wang, Hsiang-Yin Chen Article 107651 Reviews（综述） 7 A systematic review and meta-analysis of the global epidemiology of carbapenem-resistant Escherichia coli 碳青霉烯耐药大肠埃希菌全球流行病学的系统综述和荟萃分析 Mikaela M. Walker, Jason A. Roberts, Yixuan Li, Fekade B. Sime Article 107668 8 Molecular mechanisms of resistance and tolerance of Staphylococcus aureus to daptomycin 金黄色葡萄球菌对达托霉素耐药和耐受的分子机制 Candice Lim, Geoffrey W. Coombs, Shakeel Mowlaboccus Article 107678 Full Length Articles（长篇论著） 9 Antimicrobial peptide CATH-1 combats Streptococcus suis by targeting serine/threonine kinase 抗菌肽CATH-1通过靶向丝氨酸/苏氨酸激酶对抗猪链球菌 Yi Lu, Xiaoying Yu, Yandi Pan, Hang Yin, ... Rendong Fang Article 107656 10 The antiarrhythmic drugs dronedarone and amiodarone exhibit potent in vitro and in vivo activity against Clostridioides difficile 抗心律失常药物决奈达隆和胺碘酮对艰难梭菌表现出强效的体内外活性 Ahmed A. Abouelkhair, Nader S. Abutaleb, Mohamed N. Seleem Article 107649 11 Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Türkiye: A multi-centre retrospective matched-cohort study 头孢他啶-阿维巴坦与土耳其其他适当抗菌疗法治疗产OXA-48或KPC的肠杆菌目感染的比较：一项多中心回顾性匹配队列研究 Abdullah Tarık Aslan, Elif Seren Tanriverdi, Sibel Yıldız Kaya, Gozde Dalgan, ... Murat Akova Article 107650 12 An easy-to-use predictive score for identifying patients at risk of suboptimal linezolid exposure and candidates for therapeutic drug monitoring 一种易于使用的预测评分，用于识别存在利奈唑胺暴露不足风险及需进行治疗药物监测的患者 Daniel Fresán, Luisa Sorlí, Jaume Barceló-Vidal, Ana Rodrigo-Moreno, ... Sonia Luque Article 107661 13 Urinary exosome-derived microRNAs as biomarkers of tenofovir disoproxil fumarate (TDF)-induced renal toxicity in people with HIV-1 尿液外泌体衍生的微小RNA作为HIV-1感染者使用富马酸替诺福韦二吡呋酯（TDF）引起肾毒性的生物标志物 José L. Casado, Pilar Vizcarra, Francisco J. Hernández-Walias, José Manuel del Rey, ... Alejandro Vallejo Article 107654 14 Global genomic epidemiology of carbapenemase-producing Klebsiella pneumoniae, 1996–2023 1996-2023年产碳青霉烯酶肺炎克雷伯菌的全球基因组流行病学 Yuxia Shi, Dongxiao Ru, Minge Wang, Shengliang Cao, ... Jianbiao Lu Article 107657 15 Two Tail Protein-Derived Capsule Depolymerases From Phage vB_KpnS_GH-K1 are Effective Against Pneumonia Caused by K2 Serotype Klebsiella pneumoniae 来自噬菌体vB_KpnS_GH-K1的两种尾蛋白衍生的荚膜多糖解聚酶对K2血清型肺炎克雷伯菌引起的肺炎有效 Guiyang Ge, Hongbei Ge, Jianhui Xu, Bing Yue, ... Rui Du Article 107662 16 Discrepancy between WGS-based genotypic and phenotypic drug susceptibility testing of first and second-line drugs for Mycobacterium tuberculosis: Limited impact of unknown resistance mechanisms 结核分枝杆菌一线和二线药物基于全基因组测序的基因型与表型药物敏感性测试之间的差异：未知耐药机制的影响有限 Ruimin Hong, Peng Xu, Wenjie Lai, Chi Wu, ... Qian Gao Article 107666 17 Consumption and expenditure on fidaxomicin and oral vancomycin for Clostridioides difficile infection: A 12-year longitudinal study of 43 countries and regions 43个国家和地区12年艰难梭菌感染使用菲达霉素和口服万古霉素的消费和支出情况纵向研究 Yin Zhang, Xue Li, Angel Y.S. Wong, Vincent K.C. Yan, ... Wai K. Leung Article 107664 18 Genome-wide insight into the evolution and global transmission of tigecycline resistant tet(X4)-carrying Klebsiella species across reservoirs 全基因组视角下携带耐替加环素tet(X4)的克雷伯菌属在各储存库中的进化与全球传播 Yuye Wu, Yawen Yu, Xueqian He, Weifang Mao, ... Zhi Ruan Article 107665 19 Combined disk-based tests for phenotypic identification of KPC variants in Enterobacterales 基于联合药敏试验的肠杆菌目中KPC变异体的表型鉴定 Feng Yang, Li Ding, Siquan Shen, Chengkang Tang, ... Fupin Hu Article 107663 20 Impact of antimicrobial resistance measures and the emergence of COVID-19 on antimicrobial use throughout the Japanese population: A retrospective cohort study using a national claims database 抗菌药物耐药性措施的实施及新冠疫情的出现对日本全民抗菌药物使用的影响：一项使用国家索赔数据库的回顾性队列研究 Ryuji Koizumi, Shinya Tsuzuki, Yusuke Asai, Kensuke Aoyagi, Norio Ohmagari Article 107667 21 Ceftazidime-avibactam resistance among clinical isolates of Citrobacter freundii, Morganella morganii, Providencia spp. and Serratia marcescens across five continents: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2016–2023 2016-2023年抗菌药物测试领导与监测（ATLAS）项目数据：五大洲弗氏柠檬酸杆菌、摩氏摩根菌、普罗维登斯菌属和产气肠杆菌临床分离株对头孢他啶-阿维巴坦的耐药性 Hao-En Jan, Jiun-Ling Wang, Nan-Yao Lee, Shun-Chung Hsueh, ... Po-Ren Hsueh Article 107669 22 Impact of DNA-stored mutations on virological response in virologically suppressed PWH in the switch to modern regimens DNA储存突变对病毒抑制的HIV感染者转换至现今治疗方案时病毒学反应的影响 Francesca Lombardi, Elio Gentilini Cacciola, Federica Carli, Francesco Saladini, ... Maria Mercedes Santoro Article 107670 23 NucS Thr74Ile confers mutator phenotype in a globally disseminated clinical Mycobacterium abscessus subsp. abscessus clone NucS Thr74Ile在全球传播的临床脓肿分枝杆菌脓肿亚种克隆中赋予突变表型 Juan Li, Junsheng Fan, Zhili Tan, Anqi Li, ... Haiqing Chu Article 107677 24 Adverse effects of posaconazole on adrenal steroid biosynthesis: An integrative approach using FAERS-based pharmacovigilance and systematic review with meta-analysis of randomised controlled trials 泊沙康唑对肾上腺类固醇生物合成的不良影响：基于FAERS的药物警戒和随机对照试验系统综述与荟萃分析的综合方法 Yuki Nakano, Kazumasa Kotake, Yuki Asai, Masayuki Murata, ... Hirotsugu Hasuwa Article 107676 25 SU3327: A multi-target compound targeting bacterial menaquinone and DNA SU3327：一种靶向细菌甲基萘醌和DNA的多靶点化合物 Shuge Wang, Ke Zhao, Ziqi Chen, Chengtao Sun, ... Dejun Liu Article 107679 26 blaKPC-2 amplification and a novel mrcA mutation drive Cefiderocol heteroresistance in ST11 CRKP blaKPC-2扩增和一种新型mrcA突变驱动ST11碳青霉烯耐药肺炎克雷伯菌对头孢地尔的异质性耐药 Yuxuan Liu, Hanxu Hong, QianBin Dai, Linping Fan, ... Yang Liu Article 107682 27 P1-like phage-plasmids drive blaCTX-M-27 transmission through lysogenic conversion and transposition P1样噬菌体质粒通过溶原性转换和转座驱动blaCTX-M-27传播 Zengfeng Zhang, Chunlei Shi Article 107686 28 Streptomyces taklimakanensis sp. nov. TRM43335 produces 3-indole carbaldehyde a promising inhibitor of carbapenem-resistant Acinetobacter baumannii: In vitro and in vivo evaluation 塔克拉玛干沙漠放线菌新种Streptomyces taklimakanensis sp. nov. TRM43335产生3-吲哚甲醛——一种有前景的碳青霉烯耐药鲍曼不动杆菌抑制剂：体内外评估 Yanchun Qin, Wen ting Zhou, Ling Wang, Shengqiang Yang, ... Hong Zeng Article 107685 Short Communications（短篇通讯） 29 Fluconazole exposure during mechanical circulatory support (MCS) device insertion 机械循环支持（MCS）装置植入期间的氟康唑暴露 Kelly A. Cairns, Kate Morton, Trisha N. Peel, Iain J. Abbott, ... Michael J. Dooley Article 107647 30 Evaluation of sulbactam-durlobactam disk diffusion and broth microdilution methods for Acinetobacter baumannii 评估磺苄西林-杜洛巴坦对鲍曼不动杆菌的纸片扩散法和肉汤微量稀释法 Xiaolan Hong, Xinying Wang, Xin Xiang, Siquan Shen, ... Yan Guo Article 107659 Letters to the Editor（读者来信） 31 Comment on “Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Turkiye: A multi-centre retrospective matched-cohort study” 对“土耳其头孢他啶-阿维巴坦与其他适当抗菌疗法治疗产OXA-48或KPC的肠杆菌目感染的比较：一项多中心回顾性匹配队列研究”的评论 S. Dhanya Dedeepya, Vaishali Goel, Nivedita Nikhil Desai Article 107671 32 Emergence of TMexCD-TOprJ-producing Vibrio furnissii in retail shellfish 零售贝类中出现产TMexCD-TOprJ的弗尼斯弧菌 Haotian Deng, Zhongpeng Cai, Kexin Li, Ludan Xiao, ... Shaowen Li Article 107680 International Journal of Antimicrobial Agents Volume 67, Issue 2 国际抗微生物制剂杂志 67卷 2期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/2 1 Title Page & Editorial Board 标题页与编委会 Article 107727 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与信息页） 2 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page 国际抗菌化疗学会（ISAC）新闻与信息页 Article 107719 Systematic Reviews and Meta-analyses（系统综述与荟萃分析） 3 Ceftazidime/avibactam and ceftolozane/tazobactam for severe paediatric infections: A systematic review, meta-analysis, and evidence map 头孢他啶/阿维巴坦与头孢洛扎/他唑巴坦治疗儿童重症感染：一项系统评价、荟萃分析及证据图谱研究 Paula Pimenta-de-Souza, Alice Ramos-Silva, Valcieny Sandes, Patrícia Portella, ... Elisangela Costa Lima Article 107710 Full Length Articles（长篇论著） 4 Downregulation of an NfsA-like nitroreductase causes metronidazole resistance in Gardnerella vaginalis NfsA样硝基还原酶下调可导致阴道加德纳菌对甲硝唑耐药 Ana Paunkov, Anna-Lena Mayr, Vera Oberbauer, Timo Schwebs, ... David Leitsch Article 107681 5 Machine–learning and gene–synergy networks reveal interpretable drivers of antibiotic resistance in Staphylococcus aureus 机器学习与基因协同网络揭示金黄色葡萄球菌抗生素耐药性的可解释驱动因素 Jie Xu, Yuan Li, Ying Wang, Fang Liu, ... Haiyan Yang Article 107690 6 Enhanced molecular surveillance for gonococcal resistance during doxycycline post-exposure prophylaxis implementation 在实施多西环素暴露后预防措施期间加强对淋球菌耐药的分子监测 Ziyuan Zhao, Leshan Xiu, Junping Peng Article 107689 7 Fosfomycin-based combinations against carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Correlating in vitro synergy with clinical outcomes 以磷霉素为基础的联合用药治疗产碳青霉烯酶肺炎克雷伯菌血流感染：体外协同作用与临床预后的相关性 Melike Törüyenler Coşkunpınar, Güle Çınar, Duygu Öcal, İsmail Balık Article 107687 8 EnvZ mutation–driven downregulation of catecholate siderophore receptors and concurrent TonB complex repression confer cefiderocol resistance in a KPC-producing ST11-KL64 hypervirulent Klebsiella pneumoniae EnvZ突变驱动儿茶酚酸铁载体受体下调表达，同时抑制TonB复合体，使产KPC酶的ST11-KL64型高毒力肺炎克雷伯菌对头孢地尔产生耐药性 Danni Pu, Xianxia Zhuo, Rongrong Song, Chunhui Wang, ... Bin Cao Article 107693 9 Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis 治疗肾盂肾炎和复杂性尿路感染的抗生素类别比较：一项系统综述和荟萃分析 Digbijay Kunwar, Itay Zahavi, Judit Olchowski, Hagar Dallasheh, Mical Paul Article 107696 10 Enhancing meropenem therapy in critical care: A retrospective study of PK/PD target attainment and therapeutic drug monitoring 强化重症监护病房中美罗培南的治疗：一项关于药代动力学/药效学目标达成情况及治疗药物监测的回顾性研究 Jingli Liao, Chao Li, Jingxian Liu, Wei Wu, ... Lixia Li Article 107697 11 Zinc deficiency reverses biofilm azole resistance in Candida albicans 锌缺乏可逆转白色念珠菌生物膜对唑类药物的耐药性 Yingzhe Wang, Shigan Ye, Yuan Deng, Yingting Huang, Xiaoliang Zhu Article 107695 12 Development of ceftazidime–avibactam resistance driven by conversion of blaKPC-2 to blaKPC-78 during treatment of ST463 carbapenem-resistant Pseudomonas aeruginosa infection 治疗ST463型碳青霉烯类耐药铜绿假单胞菌感染过程中，因blaKPC-2基因突变为blaKPC-78基因而引发的头孢他啶-阿维巴坦耐药性的产生 Haotian Xu, Tingjuan Zhang, Xueying Cui, Jingyi Guo, ... Xi Li Article 107703 13 ATP-binding cassette transporters mediate and regulate metronidazole resistance in Clostridioides difficile ATP结合盒转运蛋白介导并调控艰难梭菌对甲硝唑的耐药性 Teng Xu, Ying Zhou, Qingqing Xu, Li Wang, ... Haihui Huang Article 107709 14 Regorafenib, a multitargeted kinase inhibitor, inhibits enterovirus 71 infection by suppressing the MAPK pathway 瑞戈非尼（Regorafenib）作为一种多靶点激酶抑制剂，可通过抑制丝裂原活化蛋白激酶（MAPK）通路来抑制肠道病毒71型感染 Xinyu Zhang, Yuanyuan Cao, Yu Liu, Shengqun Deng, ... Qi Tang Article 107711 Short Communications（短篇通讯） 15 Effect of ibuprofen on the pharmacokinetics of intravenous flucloxacillin in healthy adults 布洛芬对健康成年人静脉注射氟氯西林药代动力学的影响 Alison Boast, Amy Legg, James McCarthy, Jason A Roberts, ... Amanda Gwee Article 107684 16 Formation of a novel multiresistance plasmid co-carrying tigecycline, carbapenem, and other resistance genes by recombination during conjugative transfer in Klebsiella pneumoniae 肺炎克雷伯菌在接合转移过程中通过重组形成一种共携带替加环素、碳青霉烯类及其他耐药基因的新型多重耐药质粒 Runhao Yu, Zhong Chen, Stefan Schwarz, Hong Yao, ... Xiang-Dang Du Article 107683 17 Vancomycin clearance compared to creatinine clearance by timed urine collection in the intensive care unit 重症监护室中通过定时尿液收集法比较万古霉素清除率与肌酐清除率 Andrew Chantha Hean, Rinoj Mathew, Frank Chu, Linda Awdishu Article 107704 18 Risk of infective endocarditis in oncohaematological patients undergoing active treatment with Enterococcus faecalis bloodstream infection: A retrospective multicentre study 接受积极治疗的血液肿瘤患者合并屎肠球菌（Enterococcus faecalis）血流感染时发生感染性心内膜炎的风险：一项回顾性多中心研究 Miguel Ángel Consuegra Pérez, Sara Grillo, Alexander Rombauts, María Alba Rivera Martínez, ... Laura Escolà-Vergé Article 107706 Letters to the Editor（致编辑的信） 19 In reply to the letter to editor regarding “Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Turkiye: A multi-centre retrospective matched-cohort study” 针对就《土耳其头孢他啶-阿维巴坦与其他适宜抗菌疗法治疗产OXA-48或KPC肠杆菌科感染的对比：一项多中心回顾性匹配队列研究》一文致编辑的信的回复 Abdullah T. Aslan, Patrick N.A. Harris, David L. Paterson Article 107691 20 Aztreonam–avibactam pharmacokinetics during extracorporeal membrane oxygenation support: First insights from a case report 体外膜肺氧合支持期间氨曲南-阿维巴坦的药代动力学特征：首例病例报告的初步见解 Alba Pau-Parra, Sònia Luque, Laura Doménech, María Martínez-Pla, ... Jordi Riera Article 107692 21 Comments on ‘Acute kidney injury associated with colistin sulphate vs. polymyxin B sulphate therapy: A real-world, retrospective cohort study’ 对“硫酸黏菌素与硫酸多黏菌素B治疗相关急性肾损伤：一项真实世界回顾性队列研究”的评论 Genzhu Wang Article 107702 22 Superintegron of Vibrio paracholerae as a reservoir of antibiotic resistance genes 副霍乱弧菌（或拟霍乱弧菌）超级整合子作为抗生素耐药基因的储存库 Sergio Mascarenhas Morgado, Erica Lourenço da Fonseca, Ana Carolina Paulo Vicente Article 107708 23 Clinical outcomes of metronidazole dosing strategies in obese patients with Bacteroides bloodstream infections 肥胖患者脆弱拟杆菌（Bacteroides）血流感染时甲硝唑不同给药策略的临床疗效 Sunish Shah, Rachel V. Marini, Dayna McManus, Ryan K. Shields, ... Tyler Tate Article 107701 Corrigendum（勘误表） 24 Corrigendum to “Impact of antimicrobial resistance measures and the emergence of COVID-19 on antimicrobial use throughout the Japanese population: A retrospective cohort study using a national claims database” [International Journal of Antimicrobial Agents Volume 67(2026)107667] 对《抗菌药物耐药性评估及新冠疫情的爆发对日本全民抗菌药物使用情况的影响：一项基于国家医保理赔数据库的回顾性队列研究》[《国际抗微生物制剂杂志》第67卷（2026年）第107667篇]的勘误说明 Ryuji Koizumi, Shinya Tsuzuki, Yusuke Asai, Kensuke Aoyagi, Norio Ohmagari Article 107694 International Journal of Antimicrobial Agents Volume 67, Issue 3 国际抗微生物制剂杂志 67卷3期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/3 1 Title Page & Editorial Board 目录与编委会 Article 107753 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与资讯页面） 2 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page 国际抗菌化疗学会（ISAC）新闻与资讯页面 Article 107746 Hot Topic（热点） 3 Artificial intelligence and machine learning in antimicrobial discovery, resistance prediction, and precision therapy 人工智能与机器学习在抗菌药物发现、耐药性预测及精准治疗中的应用 Reema Singh, Yu-Wei Lin, Jinxin Zhao, Jian Li Article 107715 Reviews（综述） 4 Pharmacokinetics and pharmacodynamics of bacteriophage therapy: A scoping review 噬菌体治疗的药代动力学和药效学：一项范围综述 Andrew T Nguyen, Nicita Mehta, KaiLan Mackey, Thomas Cummiskey, ... Jason Young Article 107705 5 Effect of probiotic strain, duration, and dose on preventing ICU-acquired infection: A scoping review 益生菌菌株、疗程及剂量对预防重症监护病房（ICU）获得性感染的影响：一项范围综述 Aqdar Mufareh Al-Aklabi, Sara Muteb Alotaishan, Yasmin Youssuf Al-Gindan, Rabie Yousif Khattab Article 107714 Full Length Articles（完整论著） 6 Pharmacokinetics of ampicillin, sulbactam and combined ampicillin/sulbactam in subcutis, muscle and plasma: A microdialysis trial in healthy volunteers 氨苄西林、舒巴坦及氨苄西林/舒巴坦联合用药在皮下、肌肉和血浆中的药代动力学：一项健康志愿者微透析试验 Anselm Jorda, Lena Pracher, Marlene Prager, Felix Bergmann, ... Valentin al Jalali Article 107716 7 Beneficial effects of a compound probiotic in Helicobacter pylori-infected patients aged over 40 years: An open-label randomised clinical trial 复合益生菌对40岁以上幽门螺杆菌感染患者的有益作用：一项开放标签随机临床试验 Chenghai Yang, Jie Cheng, Meng Zhang, Bingyun Lu, ... Ye Chen Article 107712 8 Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis 内脏利什曼病（黑热病）后皮肤利什曼原虫病患者的皮肤药代动力学与药效学 Wan-Yu Chu, Om Prakash Singh, Shyam Sundar, Krishna Pandey, ... Thomas P. C Dorlo Article 107713 9 Amodiaquine hydrochloride facilitates mycobacterial clearance via triggering autophagy in macrophages 盐酸阿莫地喹通过触发巨噬细胞自噬促进分枝杆菌清除 Hongxuan Yan, Jinfeng Yuan, Shujuan Duan, Fuzhen Zhang, ... Mengqiu Gao Article 107720 Short Communications（短篇通讯） 10 Risk factors for bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii in ICU patients with any site colonisation: a prospective observational study 重症监护病房（ICU）患者任何部位定植碳青霉烯耐药鲍曼不动杆菌造成血流感染的危险因素：一项前瞻性观察研究 Giusy Tiseo, Valentina Galfo, Aurelio Lepore, Manuela Pogliaghi, ... Marco Falcone Article 107717 11 Resistance to sulbactam/durlobactam in carbapenem-resistant Acinetobacter baumannii in treatment-naive setting: in vitro data and genomic insights from Italian bloodstream isolates 初次用药背景下耐碳青霉烯鲍曼不动杆菌对舒巴坦/杜洛巴坦的耐药性：来自意大利血流感染分离株的体外数据及基因组见解 Gabriele Bianco, Gherard Batisti Biffignandi, Matteo Boattini, Sara Comini, ... Paolo Gaibani Article 107718 12 Real-world daptomycin use with a focus on muscle toxicity: A multicentric retrospective study 聚焦肌肉毒性的达托霉素实际使用情况：一项多中心回顾性研究 C. Airaud, E. Demay, V. Dias Meireles, D. Luque Paz, ... A. Bacle Article 107721 International Journal of Antimicrobial Agents Volume 67, Issue 4 国际抗微生物制剂杂志 67卷4期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/4 1 Title Page & Editorial Board 目录与编者按 Article 107775 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与信息） 2 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page 国际抗菌化疗学会（ISAC）新闻与信息 Article 107765 Hot Topic（热点） 3 Phage therapy in China: Arming the One Health approach 中国噬菌体疗法：助力“同一健康”策略实施 Na Li, Qimao Yang, Bijie Hu, Tongyu Zhu, Nannan Wu Article 107731 Global Landscape of Phage Therapy（噬菌体疗法的全球概况） 4 CRISPR/Cas9-engineered Salmonella phage displaying antimicrobial peptide LL37 for enhanced antibacterial activity 利用CRISPR/Cas9技术改造的沙门氏菌噬菌体，展示出抗菌肽LL37，用以增强抗菌活性 Su Jin Jo, Se Chang Park, Sang Guen Kim Article 107734 5 Phage resistance bidirectionally altered antibiotic susceptibility in Klebsiella pneumoniae via galE mutation 噬菌体抗性通过galE基因突变双向改变肺炎克雷伯菌的抗生素敏感性 Braira Wahid, Sue C. Nang, Jinxin Zhao, Zhi Ying Kho, ... Jian Li Article 107738 Reviews（综述） 6 Resistance of uropathogens to gepotidacin: A systematic review of in vitro antimicrobial susceptibility studies 尿路病原体对吉培西林（gepotidacin，一种新型抗菌药）的耐药性：体外抗菌敏感性研究的系统综述 Matthew E. Falagas, Laura T. Romanos, Eleni D. Katritsi, Iva D. Tzvetanova Article 107723 Full Length Articles（完整论著） 7 Identification of KPC-271, a novel KPC variant conferring ceftazidime-avibactam resistance while restoring carbapenem susceptibility in ST15-KL19 Klebsiella pneumoniae 新型KPC变体KPC-271的鉴定：该变体使ST15-KL19型肺炎克雷伯菌对头孢他啶-阿维巴坦产生耐药性，同时恢复其对碳青霉烯类的敏感性 Hongjian Ou, Siquan Shen, Chengkang Tang, Weiwei Yang, ... Fupin Hu Article 107725 8 Rapid detection of NDM-producing carbapenem-resistant Escherichia coli using MALDI-TOF MS combined with machine learning techniques 基质辅助激光解吸电离飞行时间质谱（MALDI-TOF MS）结合机器学习技术快速检测产新德里金属β-内酰胺酶（NDM）的碳青霉烯类耐药大肠杆菌 Rongrong Dong, Yifei Wang, Lei Song, Jiayin Wang, ... Jiancheng Xu Article 107726 9 Global distribution and genomic architectures of plasmid-mediated quinolone resistance genes in Shigella from 1998 to 2025 1998年至2025年志贺氏菌中质粒介导的喹诺酮类耐药基因的全球分布及基因组结构特征 Juan Geng, Cheng Cheng, Xu Liu, Jinzhao Long, ... Guangcai Duan Article 107737 Short Communications（快报） 10 Global epidemiological trend of Klebsiella pneumoniae ST23: Emergence of KL57 lineage carrying dual carbapenemases 肺炎克雷伯菌ST23型全球流行病学趋势：携带双碳青霉烯酶的KL57谱系的出现 Shuangshuang Li, Guoli Li, Xueqian He, Yawen Yu, ... Zhi Ruan Article 107722 11 Antibiotic susceptibility of Gram-negative bacteria in cerebrospinal fluid compared with Mueller-Hinton broth and artificial cerebrospinal fluid 脑脊液中革兰氏阴性菌对Mueller-Hinton肉汤和人工脑脊液的抗生素敏感性比较 Katrin Biesner, Marija Djukic, Utz Reichard, Roland Nau, Jana Seele Article 107730 Letters to the Editor（致编辑的信） 12 Global, regional, and national burden of multidrug-resistant organisms, 1990–2021 1990 - 2021年全球、区域及国家层面多重耐药菌的疾病负担 Lian Liu, Hong Luo Article 107724 13 Beyond categorical agreement: Antibiotic-specific time to result in rapid susceptibility testing from Gram-negative positive blood cultures 超越分类一致性：针对革兰氏阴性菌血培养阳性的快速药敏试验中不同抗生素的结果检出时间 Tiziana D’Inzeo, Damiano Squitieri, Cataldo Maria Mannavola, Matteo Zelinotti, ... Brunella Posteraro Article 107735 14 Comment on “Phage therapy for KPC-producing Klebsiella pneumoniae de colonisation in high-risk patients: The KIDNAP Study Protocol” 对“针对高危患者中产KPC肺炎克雷伯菌定植的噬菌体疗法：KIDNAP研究方案”的评论 Yinjia Lou, Yiqing Han Article 107733 International Journal of Antimicrobial Agents Volume 67, Issue 5 国际抗微生物制剂杂志 67卷5期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/5 1 Title Page & Editorial Board 目录及编委会 Article 107819 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与资讯页） 2 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page 国际抗菌化疗学会（ISAC）新闻与资讯页 Article 107803 Editor's Choice（编辑精选） 3 cirA promoter disruption and SHV-12 production contribute to cefiderocol resistance in carbapenem-resistant Klebsiella pneumoniae cirA启动子破坏与SHV-12酶的产生共同导致碳青霉烯耐药肺炎克雷伯菌对头孢地尔产生耐药性 Fang Shen, Xiaochen Liu, Tailong Lei, Jingjing Quan, ... Qiucheng Shi Article 107756 Hot Topic（热点） 4 Formulating and stabilising therapeutic phages: A review 治疗性噬菌体的配制与稳定化：综述 Eleni Siafakas, Hien T.T. Duong, Jonathan R. Iredell Article 107759 Global Landscape of Phage Therapy（噬菌体疗法的全球概况） 5 Assessing carbonylation in Pseudomonas aeruginosa clinical isolates infected by bacteriophages using flow cytometry 利用流式细胞术评估受噬菌体感染的铜绿假单胞菌临床分离株中的羰基化情况 Jia Hao Yeo, Shuhua Thong, Shimin Jasmine Chung, Andrea Lay-Hoon Kwa Article 107739 AI strategies to combat AMR（应对抗菌药物耐药性的人工智能策略） 6 Causality-informed models for multidrug-resistant organism prediction: Enabling effective ICU antibiotic stewardship 基于因果关系建模的多重耐药菌预测模型：助力重症监护室（ICU）有效开展抗生素管理 Linna Wang, Xinyu Guo, Yimin Chen, Siying Li, ... Li Lu Article 107767 Reviews（综述） 7 Tissue pharmacokinetics of antifungal drugs: a review 抗真菌药物的组织药代动力学：综述 Felix Bergmann, Marlene Prager, Lena Pracher, Anselm Jorda, ... Markus Zeitlinger Article 107743 8 New-generation antibiotics and nonantibiotic strategies against carbapenemase-producing Enterobacterales: More focus on metallo-β-lactamase producers 新一代抗生素及非抗生素策略针对产碳青霉烯酶肠杆菌科细菌：更聚焦于产金属β-内酰胺酶菌种 Shio-Shin Jean, Chih-Cheng Lai, Hou-Tai Chang, Hui-Che Hsiao, ... Po-Ren Hsueh Article 107750 9 A window into resistance: The MEGA-plate as a model of evolutionary dynamics 洞见耐药性：MEGA 培养皿——一种模拟进化动态的模型 Maytham Hussein, Rafah Allobawi, James Barclay, Zhi Ying Kho, ... Tony Velkov Article 107751 Full Length Articles（长篇论著） 10 Efficacy and safety of intracameral amphotericin B for fungal keratitis: A systematic review and meta-analysis 眼内注射两性霉素B治疗真菌性角膜炎的疗效与安全性：一项系统综述与荟萃分析 Kai-Yang Chen, Hoi-Chun Chan, Chi-Ming Chan Article 107707 11 Urine NGAL adds to serum creatinine in predicting cefepime clearance in critically ill children at high risk of acute kidney injury 尿中性粒细胞明胶酶相关脂质运载蛋白（NGAL）联合血清肌酐，可更有效地预测急性肾损伤高风险危重症儿童头孢吡肟的清除率 Horace Rhodes Hambrick, Ronaldo Morales Junior, Calise Curry, Michaela Collins, ... Sonya Tang Girdwood Article 107741 12 Integrative virtual and empirical screening to identify multi-target flavonoid quercetin-3-O-glucuronide for reducing MRSA pathogenicity 通过整合虚拟筛选与实证筛选，确定具有多靶点作用的黄酮类化合物槲皮素-3-O-葡萄糖醛酸苷可降低耐甲氧西林金黄色葡萄球菌（MRSA）的致病性 Hang Gao, Li Wang, Zeze Fu, Yun Sun, ... Yicheng Zhao Article 107744 13 Validation of limited sampling strategies for polymyxin B therapeutic drug monitoring in critical care 重症监护中多粘菌素B治疗药物监测有限采样策略的验证 Yury A. Surovoy, Inna A. Galvidis, Akmal I. Alimov, Sergei V. Tsarenko, Maksim A. Burkin Article 107740 14 Population pharmacokinetics of cefazolin and metronidazole in patients undergoing elective colorectal surgery 择期结直肠手术患者头孢唑林和甲硝唑的群体药代动力学研究 Rochelle Ryan, Scott McDonald, Steven C Wallis, Andre van Zundert, ... Jason A. Roberts Article 107742 15 Omeprazole is associated with voriconazole-associated hepatotoxicity: PPI-stratified analysis and a clinically actionable nomogram from an 848-patient cohort 奥美拉唑与伏立康唑相关肝毒性有关：基于848例患者队列的质子泵抑制剂分层分析及临床可操作的列线图 Yuhang Ding, Yanhong Meng, Huaijun Zhu, Jinping Zhang, Qiuhui Wu Article 107749 16 Treatment sequences of a phage and colistin combination trigger different evolution pathways of a multidrug-resistant Acinetobacter baumannii yielding distinct treatment outcomes 噬菌体与粘菌素（多粘菌素E）联合用药的不同治疗顺序可引发多重耐药鲍曼不动杆菌的不同进化路径，进而产生截然不同的治疗效果 Subhankar Mukhopadhyay, Xiaoxu Zhang, Kenneth K.W. To, Yannan Liu, ... Sharon S.Y. Leung Article 107745 17 L-Cycloserine, not d-Cycloserine, inhibits IscS-mediated iron–sulfur cluster biosynthesis in Escherichia coli L-环丝氨酸（而非D-环丝氨酸）抑制大肠杆菌中由IscS介导的铁硫簇生物合成 Lihe Zhang, Yongjuan Li, Yuhang Bao, Jie Feng, ... Wu Wang Article 107761 18 Molecular mechanisms and clonal distribution of cefiderocol-resistant blaNDM-carrying Escherichia coli: A multi-centre study in China 携带产头孢他啶/阿维巴坦耐药基因blaNDM的大肠杆菌的分子机制及克隆分布：中国多中心研究 Chengkang Tang, Siquan Shen, Renru Han, Dandan Yin, ... Fupin Hu Article 107762 Short Communications（短讯） 19 Present trajectories to forecasted future: A longitudinal analysis of hospital antibiotic use in China from 2013 to 2024 and projections to 2030 现状轨迹至预测未来：2013 年至 2024 年中国医院抗生素使用情况的纵向分析及至 2030 年的预测 Weibin Li, Fenqi Du, Ruowei Xiao, Weihsin Ko, ... Haishaerjiang Wushouer Article 107764 Letters to the Editor（致编辑的信） 20 Comment on ‘Pharmacokinetics of ampicillin, sulbactam, and combined ampicillin/sulbactam in subcutis, muscle, and plasma: A microdialysis trial in healthy volunteers’ 对“氨苄西林、舒巴坦及氨苄西林/舒巴坦联合用药在皮下组织、肌肉和血浆中的药代动力学：一项在健康志愿者中进行的微透析试验”的评论 Kishankumar Mahida, Snehal Rajendra Jagtap Article 107736 21 Comment on: “Therapeutic drug monitoring of isavuconazole: Trends and update” 述评：“艾沙康唑治疗药物监测：趋势与最新进展” Zhibin Xu, Shouning Zhou, Lulin Wang, Xiaohua Wang, ... Chunrong Ju Article 107732 22 Comprehensive analysis of 16S rRNA methyltransferases in Enterobacterales isolated from dogs and cats reveals co-resistance with broad-spectrum β-lactamases 对从猫狗体内分离出的肠杆菌目细菌中16S rRNA甲基转移酶的全面分析揭示其与广谱β-内酰胺酶共存耐药性 Fábio Parra Sellera, Yawen Yu, Yingying Zhang, Luciana Sartori, ... João Pedro Rueda Furlan Article 107747 23 Comment on "Effect of probiotic strain, duration, and dose on preventing ICU-acquired infection: A scoping review" 评论：“益生菌菌株、疗程和剂量对预防重症监护病房获得性感染的影响：一项范围综述” Jiayi Yu Article 107758 24 Comment on “Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis” 对《肾盂肾炎及复杂性尿路感染治疗中不同类别抗生素的比较：一项系统综述与荟萃分析》一文的评论 Qiao Chen Article 107770 Corrigendum（勘误表） 25 Corrigendum to “Phage therapy for KPC-producing Klebsiella pneumoniae decolonization in high-risk patients: The KIDNAP Study Protocol - A prospective feasibility and proof of concept study in the Brazilian context” [International Journal of Antimicrobial Agents Volume 67(2026)107673] 对“针对产KPC酶肺炎克雷伯菌定植清除的高危患者实施噬菌体治疗：《KIDNAP研究方案》——巴西背景下的一项前瞻性可行性及概念验证研究”[《国际抗微生物制剂杂志》第67卷（2026年）第107673篇]的勘误 Iris Najjar, Larissa Simão Gandolpho, Jôiciglecia Pereira dos Santos, Camila de Paula Siqueira, ... Ana C. Gales Article 107766 International Journal of Antimicrobial Agents Volume 67, Issue 6 国际抗微生物制剂杂志 67卷 6期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/6 1 Title Page & Editorial Board 目录及编委会 Article 107853 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与信息页） 2 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page 国际抗菌化疗学会（ISAC）新闻与信息页 Article 107829 Editor's Choice（编辑推荐） 3 Mobile colistin resistance in New Zealand without local agricultural colistin use: Genomic insights into mcr-carrying plasmids and their global context, 1984–2024 新西兰本地未使用粘菌素农业用药却出现粘菌素耐药菌移动现象：关于携带mcr基因质粒及其1984-2024年全球背景的基因组学见解 Jenny Szeto, Rhys T. White, Hermes Perez, Allan Hardaker, ... Zuyu Yang Article 107801 Hot Topic（热点） 4 Access to new antibacterials in 10 Asian countries: An Asian network for surveillance of resistant pathogens study 10个亚洲国家获得新型抗菌药物的情况：一项亚洲耐药病原体监测网络研究 Young Ho Lee, Helmi bin Sulaiman, Visanu Thamlikitkul, David Chien Lye, ... Kyungmin Huh Article 107769 AI strategies to combat AMR（应对抗菌药物耐药性的人工智能策略） 5 Surgical MAchine learning model for predicting Risk of postoperative infecTions in general elective surgery (SMART): A modelling study 用于预测普通择期手术术后感染风险的手术机器学习模型（SMART）：一项建模研究 Nehal Hassan, Robert Slight, Graham Morgan, Daniel Weiand, ... Sarah P. Slight Article 107768 Reviews（综述） 6 Prophylactic and therapeutic efficacy of monoclonal antibodies against avian influenza H5N1 virus 抗禽流感H5N1病毒单克隆抗体的预防和治疗功效 Antonios-Periklis Panagiotopoulos, Cleo Anastassopoulou, Kyriaki Ranellou, Ilias Mariolis, Athanasios Tsakris Article 107784 Full Length Articles（长篇论著） 7 Broad-host-range Kayvirus phages preferentially infect Staphylocococcus aureus cells with β-glycosylated WTA, the most common bacterial form in the human host 广泛宿主范围卡伊病毒噬菌体优先感染携带β-糖基化壁磷壁酸（WTA）的金黄色葡萄球菌细胞，此为人类宿主中最常见的细菌形式 Andrea Jurado, Carlos C. Gómez-Cambronero, Ana Rodríguez, Daniel Lopez, ... Lucía Fernández Article 107755 8 Characterization of KPC-176, an S171P variant derived from KPC-2, associated with ceftazidime-avibactam resistance in ST11-KL64 Klebsiella pneumoniae KPC-176的特征分析，该变异体源自KPC-2，其S171P变异与ST11-KL64型肺炎克雷伯菌对头孢他啶-阿维巴坦的耐药性相关 Yinyin Hu, Lufei Yuan, Zhaoxin Xia, Tian Wan, ... Jilu Shen Article 107773 9 Development and validation of a predictive model for profiling antibiotic resistance phenotypes of Acinetobacter baumannii strains via clinical MALDI-TOF mass spectra: A multicenter study 通过临床基质辅助激光解吸电离飞行时间质谱（MALDI-TOF MS）建立并验证预测鲍曼不动杆菌菌株抗生素耐药表型的模型：一项多中心研究 Quan Yuan, Su-Ling Liu, Luan Luan, Yue-Ting Jiang, ... Liang Wang Article 107760 10 Human serum albumin and biological fluids reduce cefiderocol activity in carbapenem-resistant gram-negative bacteria 人血清白蛋白及生物体液会降低头孢地尔对碳青霉烯类耐药革兰氏阴性菌的活性 Azadeh Varnado, Samyar Moheb, Shayra D. Sanchez, Cecilia Rodriguez, ... Maria S. Ramirez Article 107781 11 Minor non-fermenting Gram-negative bacilli in Europe, 2020–2024 (MINOFEu) 2020 - 2024年欧洲非发酵型革兰氏阴性杆菌情况（MINOFEu） Gabriele Bianco, Paulo Bastos, Konstantina Gartzonika, Eirini Christaki, ... Matteo Boattini Article 107772 12 Amphotericin B ameliorates obesity through modulating gut mycobiome dysbiosis and brown adipose tissue thermogenesis in high-fat diet-induced mice 两性霉素B通过调节高脂饮食诱导小鼠的肠道真菌群失调和棕色脂肪组织产热来改善肥胖 Yinghan Xiang, Zhouyi Wang, Jiaxin An, Qianrui Wei, ... Huajun Li Article 107780 13 Repurposing sulfamethoxazole via gold nanocluster modification for antibacterial and anti-biofilm activity against multidrug-resistant Gram-negative bacteria 通过金纳米簇修饰重新利用磺胺甲恶唑以获得针对多重耐药革兰氏阴性菌的抗菌和抗生物膜活性 Yiwen Xue, Yujing Wang, Congcong You, Yanlei Zheng, ... Tieli Zhou Article 107757 14 Do predictors of vancomycin trough concentration non-attainment differ for subtherapeutic and supratherapeutic levels? A 9-year stratified analysis in critically ill patients 对于万古霉素谷浓度未达标情况，亚治疗水平（浓度过低）与超治疗水平（浓度过高）的预测因素是否不同？一项针对危重症患者为期9年的分层分析 Yun Yang, Ying Zhu, Jun You, Jiali Zhang, ... Ping Wang Article 107779 15 Ceftazidime/avibactam-resistant carbapenem-resistant Klebsiella pneumoniae in China: A nationwide multicenter study 中国耐头孢他啶/阿维巴坦的碳青霉烯类耐药肺炎克雷伯菌：一项全国多中心研究 Rongqi Lu, Yun Wu, Ruirui Ma, Rongxiang Feng, ... Yali Liu Article 107774 16 Population pharmacokinetics and dosing regimen optimization of ceftazidime in plasma and cerebrospinal fluid of neonatal sepsis patients 新生儿败血症患者血浆及脑脊液中头孢他啶的群体药代动力学与给药方案优化 Zuo Wang, Yingying Xin, Ying Deng, Ting Xia, ... Yang Wang Article 107783 17 Global burden of antimicrobial resistance in lower respiratory infections: A systematic analysis for the Global Burden of Disease Study 2021 下呼吸道感染中抗菌药物耐药性的全球负担：2021年全球疾病负担研究的系统分析 Weidong Qin, Hao Wang, Kunpeng Lv, Sa Liu, ... Yuguo Chen Article 107786 18 Spontaneous mutations to delamanid and pretomanid resistance in Mycobacterium tuberculosis: SNPs confer high-level resistance 结核分枝杆菌对德拉马尼和普托马尼自发产生耐药性的突变：单核苷酸多态性（SNPs）导致高水平耐药性 Qian Zhang, Peng Xu, Xuecong Zhang, Rui Pi, ... Qian Gao Article 107789 19 ESBL-producing Escherichia coli bacteraemic urinary tract infections: Clinical and economic burden and antimicrobial stewardship opportunities in a retrospective cohort study 产超广谱β-内酰胺酶（ESBL）大肠埃希菌致血行性尿路感染：一项回顾性队列研究中的临床与经济负担及抗菌药物管理机遇 Silvia Gómez-Zorrilla, Grethel Rodríguez-Cabalé, Inmaculada López Montesinos, Soukaina Sara Alanti, ... Juan P. Horcajada Article 107787 20 Distribution of piperacillin-tazobactam into cerebrospinal, peritoneal, and pleural fluid in children aged 0–18 years 0至18岁儿童哌拉西林-他唑巴坦在脑脊液、腹水和胸腔积液中的分布情况 Jinglei Wang, Wenyu Yang, Alice Lei, Kiera Harwood, ... Amanda Gwee Article 107793 21 Letermovir for CMV prophylaxis after haploidentical HSCT: A prospective study of direct and indirect effects 来特莫韦用于单倍体相合造血干细胞移植后巨细胞病毒预防：一项关于直接和间接效应的前瞻性研究 Tong Cui, Chengsen Cai, Shiyuan Zhou, Yuejun Liu, ... Xiaojin Wu Article 107790 22 Efficacy, safety, and population pharmacokinetics of eravacycline for carbapenem-resistant organism infections in immunocompromised hosts: A multicenter prospective cohort study 依拉环素治疗免疫功能低下宿主碳青霉烯类耐药菌感染的疗效、安全性及群体药代动力学：一项多中心前瞻性队列研究 Yifu Hou, Lijuan Zhang, Hong Li, Linhong Zhong, ... Lingai Pan Article 107795 Short Communications（简讯） 23 Early risk stratification in Staphylococcus aureus bacteraemia: External validation of the FEN-AUREUS classification in a UK cohort 金黄色葡萄球菌菌血症的早期风险分层：FEN-AUREUS分类在英国队列中的外部验证 Belén Gutiérrez-Gutiérrez, Luis Eduardo López-Cortés, Giulia Zumbo, Jesús Rodríguez-Baño, Clark D. Russell Article 107778 24 Global genomic surveillance of tigecycline resistance gene tet(X) in Salmonella enterica 全球范围内对肠沙门氏菌中替加环素耐药基因tet(X) 的基因组监测 Jing Wang, Wenyi Li, Jia-Qing Hou, Peng-Yun Shao, ... Qiuchun Li Article 107794 25 Plasma and subcutaneous interstitial fluid vancomycin and gentamicin concentrations in three patients undergoing open abdominal aortic aneurysm repair 三例接受开放性腹主动脉瘤修复术患者血浆及皮下组织间液中万古霉素和庆大霉素的浓度 Rochelle Ryan, Paul Jarrett, Melissa Lassig-Smith, Steven C. Wallis, ... Jason A. Roberts Article 107796 Letters to the Editor（致编辑的信） 26 Comment on “Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis” 《肾盂肾炎及复杂性尿路感染治疗中不同类别抗生素的比较：一项系统综述与荟萃分析》述评 Chandana Maji, Hariharan Srinivasan, Aishwarya Biradar, Reenoo Jauhari Article 107771 27 Clonal spread of NDM-1-producing Moellerella wisconsensis between cattle farm and mutton 产NDM-1的威斯康星莫勒氏菌在养牛场与羊肉之间的克隆传播 Ludan Xiao, Xingxing Zhang, Chao Yue, Zhongpeng Cai, ... Yi-Yun Liu Article 107748 28 In reply to the letter to editor regarding ‘Pharmacokinetics of ampicillin, sulbactam, and combined ampicillin/sulbactam in subcutis, muscle, and plasma: A microdialysis trial in healthy volunteers’ 回复关于“氨苄西林、舒巴坦及氨苄西林/舒巴坦联合用药在皮下、肌肉和血浆中的药代动力学：一项健康志愿者微透析试验”的致编辑信 Anselm Jorda, Markus Zeitlinger, Valentin al Jalali Article 107752 29 Reply to the letter to the editor regarding ‘Acute kidney injury associated with colistin sulfate vs. polymyxin B sulfate therapy: A real-world, retrospective cohort study’ 回复：关于“硫酸黏菌素与硫酸多黏菌素B治疗相关急性肾损伤：一项真实世界回顾性队列研究”的致编辑的信 Yanfang Zhang, Ziqi Ye, Saiping Jiang Article 107763 30 In reply to the letter to editor regarding: Effect of probiotic strain, duration, and dose on preventing ICU-acquired infection: A scoping review 回复关于《益生菌菌株、疗程及剂量对预防重症监护病房获得性感染的影响：一项范围综述》一文致编辑的来信 Aqdar Mufareh Al-Aklabi, Sara Muteb Alotaishan, Yasmin Youssuf Al-Gindan, Rabie Yousif Khattab Article 107782 31 Comment on “Beneficial effects of a compound probiotic in Helicobacter pylori-infected patients aged over 40 years: An open-label randomized clinical trial” 对“复合益生菌对40岁以上幽门螺杆菌感染患者的有益作用：一项开放标签随机临床试验”的评论 Palavardhan Peddapalegani, Raghav Gupta, Priyanka Bansal, Pankaj Nainwal, Hariharan Srinivasan Article 107785 32 Comment on ‘Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis’ 对“用于治疗肾盂肾炎和复杂性尿路感染的抗生素类别比较：一项系统综述和荟萃分析”的评论 Congyao Wang, Jinwen Chen, Huizhong Yang, Mengjin Jiang Article 107777 33 In reply to the Letter to Editor regarding “Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis” 回复关于“治疗肾盂肾炎和复杂性尿路感染的抗生素类别比较：一项系统综述和荟萃分析”的致编辑信 Itay Zahavi, Digbijay Kunwar, Judit Olchowski, Hagar Dallasheh, Mical Paul Article 107791 34 In Reply to the Letter to Editor Regarding "Phage Therapy for KPC-Producing Klebsiella pneumoniae Decolonization in High-Risk Patients: The KIDNAP Study Protocol - A Prospective Feasibility and Proof of Concept Study in the Brazilian Context" 回复关于“噬菌体疗法用于高危患者产KPC肺炎克雷伯菌的根除：《KIDNAP研究方案》——巴西背景下的一项前瞻性可行性及概念验证研究”的致编辑信 Iris Najjar, Larissa Simão Gandolpho, Jôiciglecia Pereira dos Santos, Camila de Paula Siqueira, ... Ana C Gales Article 107788 International Journal of Antimicrobial Agents Volume 67, Issue 7 国际抗微生物制剂杂志 67卷 7期 https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/7 1 Title Page & Editorial Board 目录与编委会 Article 107862 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与信息页） 2 International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page 国际抗菌化疗学会（ISAC）新闻与信息页 Article 107845 Full Length Articles（长篇论著） 3 Targeting the human protein disulfide isomerase A3 as a broad-spectrum antiviral approach against human respiratory viruses 以人蛋白二硫键异构酶A3为靶点，开发针对人类呼吸道病毒的广谱抗病毒方法 Giulia Sibille, Arianna Maggiora, Giorgia Cimato, Anna Luganini, Giorgio Gribaudo Article 107802 4 Comparative outcomes of daptomycin and linezolid in vancomycin-resistant enterococcal intra-abdominal infections with bacteraemia 达托霉素与利奈唑胺治疗耐万古霉素肠球菌所致伴菌血症的腹腔内感染的疗效比较 Tsung-Yu Tsai, Yu-Chung Chuang, Jia-Ling Yang, Chi-Ying Lin, ... Shan-Chwen Chang Article 107792 5 Synthetic quinolone-tethered aminoguanidine derivatives exhibit potent anti-plasmodial activity 合成的喹诺酮连接氨基胍衍生物表现出强效的抗疟原虫活性 Nanang R. Ariefta, Richard M. Beteck, Lesetja J. Legoabe, Yoshifumi Nishikawa Article 107797 6 Association between antimicrobial resistance and in-hospital mortality in adults with bacterial infective endocarditis: A nationwide cohort study 抗菌药物耐药性与成人细菌性感染性心内膜炎住院死亡率之间的关联：一项全国性队列研究 Iván Oterino-Moreira, Francisco Javier Candel-González, Montserrat Pérez-Encinas, Susana Lorenzo-Martínez Article 107805 7 Machine learning-based prediction of multi-level anti-microbial resistance in Klebsiella pneumoniae using whole-genome sequencing data 基于全基因组测序数据，利用机器学习预测肺炎克雷伯菌的多层级抗菌药物耐药性 Xinmiao Jia, Jingjia Zhang, Jing Chen, Jun Wang, ... Qiwen Yang Article 107807 8 Investigating the role of novel alphatectiviruses in reducing carriage and transfer of antimicrobial resistance plasmids 新型α干扰病毒在减少耐药质粒携带和转移中的作用研究 Mattis Kreins-Irle, Michael Berger, Ágnes Solti-Hodován, Krishnendu Mukherjee, ... Ulrich Dobrindt Article 107806 9 A Multicenter, Randomized, Double-Blind, Imipenem/Cilastatin-Controlled Clinical Study of Cefiderocol for the Treatment of Complicated Urinary Tract Infections Caused by Gram-Negative Pathogens in Chinese Adults 关于头孢地尔治疗中国成人由革兰氏阴性菌引起的复杂性尿路感染的多中心、随机、双盲、以亚胺培南/西司他丁为对照的临床研究 Jinyi Yuan, Deyong Fan, Henglan Wu, Bei Jia, ... Yingyuan Zhang Article 107812 10 Multidrug-Resistant Acinetobacter baumannii Pneumonia in Clinical Therapy: A Systematic Review and Network Meta-analysis on Effectiveness and Safety of Different Antibiotic Combination Regimens 多重耐药鲍曼不动杆菌肺炎的临床治疗：不同抗生素联合用药方案有效性和安全性的系统综述与网络荟萃分析 Shao-Yuan Hao, Hau-Yu Lin, Po-I Yeh, Hui-Chuan Hsiao, ... Po-Liang Lu Article 107815 11 Population pharmacokinetics of polymyxin B in critically ill patients with multi–drug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa infections 多药耐药（MDR）鲍曼不动杆菌和铜绿假单胞菌感染危重患者中多粘菌素B的群体药代动力学 Puteri Juanita Zamri, Saskia A. Wölky, Maria P. Hernandez-Mitre, Xin Liu, ... Mohd Hafiz Abdul-Aziz Article 107816 Short Communications（短讯） 12 Model-informed cefepime dosing in paediatric patients receiving continuous renal replacement therapy 接受连续性肾脏替代治疗的儿科患者的头孢吡肟模型指导给药 Ronaldo Morales Junior, Shannon Reinert, Emily Diseroad, Erin Schuler, ... H. Rhodes Hambrick Article 107809 13 Aggressive joint pharmacokinetic/pharmacodynamic target attainment of TDM-guided continuous infusion meropenem-vaborbactam monotherapy: A valuable strategy for maximizing the microbiological outcome of documented KPC-producing Enterobacterales infections? TDM指导下美罗培南-韦博巴坦持续输注单药治疗的积极联合药代动力学/药效学目标达标：一种最大化KPC产肠杆菌科细菌感染微生物学结局的有价值策略？ Milo Gatti, Cecilia Bonazzetti, Benedetta Secci, Beatrice Giorgi, ... Federico Pea Article 107811 14 Efficacy and pharmacokinetics of a stepwise isolated phage cocktail against carbapenem-resistant Klebsiella pneumoniae in a murine pneumonia model 逐步分离噬菌体鸡尾酒疗法对抗碳青霉烯耐药肺炎克雷伯菌的疗效和药代动力学：小鼠肺炎模型研究 Xin Yin, Huan Luo, Yu Feng, Qingqing Fang, Zhiyong Zong Article 107810 15 In vivo emergence of cross-resistance to ceftazidime/avibactam and cefiderocol through selection of KPC variants in Klebsiella pneumoniae clinical isolates 肺炎克雷伯菌临床分离株通过选择KPC变异株，在体内对头孢他啶/阿维巴坦和头孢地尔产生交叉耐药性 Gabriele Bianco, Jacqueline Findlay, Sara Comini, Cristina Costa, ... Matteo Boattini Article 107808 Letters to the Editor（致编辑的信） 16 In reply to the letter to the editor regarding “Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis” 回复致编辑关于“治疗肾盂肾炎和复杂性尿路感染的抗生素类别比较：一项系统综述和荟萃分析”的来信 Itay Zahavi, Digbijay Kunwar, Judit Olchowski, Hagar Dallasheh, Mical Paul Article 107800 17 Comment on “Enhancing meropenem therapy in critical care: A retrospective study of PK/PD target attainment and therapeutic drug monitoring” 对“加强重症监护病房美罗培南治疗：一项关于药代动力学/药效学目标达成情况和治疗药物监测的回顾性研究”的评论 Xuefeng Yu Article 107804 18 Analytical feasibility of linezolid quantification by LC–MS/MS using dried plasma spot microsampling 采用干血浆斑微量采样法通过液相色谱-串联质谱（LC–MS/MS）技术定量测定利奈唑胺的分析可行性研究 Anisa Bardhi, Bochra Mansour, Dimitri Schlemmer, Pascal Robidou, ... Noël Zahr Article 107799 19 Beyond parasite clearance: Three unresolved methodological challenges in cross-regional PKDL trials 突破寄生虫清除：跨区域皮肤型黑热病（PKDL）试验中三个尚未解决的方法学挑战 Ciyu Zhao, Shanshan Yuan Article 107798 20 Comment on “Nanomedicine for phage therapy: Encapsulation strategies for enhanced antimicrobial efficacy” 对"噬菌体治疗的纳米医学：增强抗菌疗效的包封策略"的评论 Wenhao Wang, Ziyu Zhao, Zhengwei Huang Article 107814 21 Comment on “ESBL-producing Escherichia coli bacteremic urinary tract infections: Clinical and economic burden and antimicrobial stewardship opportunities in a retrospective cohort study” 对"产ESBL大肠埃希菌血源性尿路感染：一项回顾性队列研究中的临床和经济负担及抗菌药物管理机会"的评论 Neeraj Singh, Monika Srivastav Article 107820